Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy

Nancy J. Newman, Patrick Yu-Wai-Man, Prem S. Subramanian, Mark L. Moster, An Guor Wang, Sean P. Donahue, Bart P. Leroy, Valerio Carelli, Valerie Biousse, Catherine Vignal-Clermont, Robert C. Sergott, Alfredo A. Sadun, Gema Rebolleda Fernández, Bart K. Chwalisz, Rudrani Banik, Fabienne Bazin, Michel Roux, Eric D. Cox, Magali Taiel, Jose Alain SahelAmore Giulia, Anand Shweta, Banik Rudrani, Barboni Piero, Biousse Valerie, Boston Hayley, Burale Asma, Carbonelli Michele, Carelli Valerio, Chen Celia, Cheng Hui-Chen, Cho Steve, Bart K. Chwalisz, Contin Manuela, D'Agati Pietro, Adam A. Debusk, De Zaeytijd Julie, Dobbs Jannah, Sean P. Donahue, Du Bois Lindreth, Esposti Simona, Fernandes Filho Alcides, Fortin Elizabeth, Gangaputra Sapna, Gibbs Deborah, Girmens Jean François, Hage Rabih, Julia A. Haller, Heilweil Gad, Hubbard I.I.I. George Baker, Hwang Jeong-Min, Jaumendreu Urquijo Laia, Jurkute Neringa, Karanjia Rustum, Khemliche Wahiba, Morgia La Chiara, Bart P. Leroy, Massini Maria, Mathias Marc, Muhammad A. Memon, Mohamed Susan, Mark L. Moster, Francisco J. Muñoz Negrete, Nancy J. Newman, O'Keefe Ghazala, Patel Shriji, Pecen Paula, Jason H. Peragallo, Plaine Lise, Preston Mary, Rebolleda Fernández Gema, Romagnoli Martina, Alfredo A. Sadun, Sahel Jose-Alain, Santa Maria Melissa, Robert C. Sergott, Prem S. Subramanian, Sun Chuanbin, Tai Katy, Tollis Heather, Tsui Irena, William R. Tucker, Vignal Clermont Catherine, Wang An-Guor, Wilkins Saige, Yu Wai Man Patrick

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Leber hereditary optic neuropathy (LHON) is an important example of mitochondrial blindness with the m.11778G>A mutation in the MT-ND4 gene being the most common disease-causing mtDNA variant worldwide. The REFLECT phase 3 pivotal study is a randomized, double-masked, placebo-controlled trial investigating the efficacy and safety of bilateral intravitreal injection of lenadogene nolparvovec in patients with a confirmed m.11778G>A mutation, using a recombinant adeno-associated virus vector 2, serotype 2 (rAAV2/2-ND4). The first-affected eye received gene therapy; the fellow (affected/not-yet-affected) eye was randomly injected with gene therapy or placebo. The primary end point was the difference in change from baseline of best-corrected visual acuity (BCVA) in second-affected/not-yet-affected eyes treated with lenadogene nolparvovec versus placebo at 1.5 years post-treatment, expressed in logarithm of the minimal angle of resolution (LogMAR). Forty-eight patients were treated bilaterally and 50 unilaterally. At 1.5 years, the change from baseline in BCVA was not statistically different between second-affected/not-yet-affected eyes receiving lenadogene nolparvovec and placebo (primary end point). A statistically significant improvement in BCVA was reported from baseline to 1.5 years in lenadogene nolparvovec-treated eyes: -0.23 LogMAR for the first-affected eyes of bilaterally treated patients (P < 0.01); and -0.15 LogMAR for second-affected/not-yet-affected eyes of bilaterally treated patients and the first-affected eyes of unilaterally treated patients (P < 0.05). The mean improvement in BCVA from nadir to 1.5 years was -0.38 (0.052) LogMAR and -0.33 (0.052) LogMAR in first-affected and second-affected/not-yet-affected eyes treated with lenadogene nolparvovec, respectively (bilateral treatment group). A mean improvement of -0.33 (0.051) LogMAR and -0.26 (0.051) LogMAR was observed in first-affected lenadogene nolparvovec-treated eyes and second-affected/not-yet-affected placebo-treated eyes, respectively (unilateral treatment group). The proportion of patients with one or both eyes on-chart at 1.5 years was 85.4% and 72.0% for bilaterally and unilaterally treated patients, respectively. The gene therapy was well tolerated, with no systemic issues. Intraocular inflammation, which was mostly mild and well controlled with topical corticosteroids, occurred in 70.7% of lenadogene nolparvovec-treated eyes versus 10.2% of placebo-treated eyes. Among eyes treated with lenadogene nolparvovec, there was no difference in the incidence of intraocular inflammation between bilaterally and unilaterally treated patients. Overall, the REFLECT trial demonstrated an improvement of BCVA in LHON eyes carrying the m.11778G>A mtDNA mutation treated with lenadogene nolparvovec or placebo to a degree not reported in natural history studies and supports an improved benefit/risk profile for bilateral injections of lenadogene nolparvovec relative to unilateral injections.

Original languageEnglish
Pages (from-to)1328-1341
Number of pages14
JournalBrain
Volume146
Issue number4
DOIs
StatePublished - 1 Apr 2023

Keywords

  • NADH dehydrogenase 4
  • leber hereditary optic neuropathy
  • lenadogene nolparvovec
  • mitochondrial DNA
  • recombinant adeno-associated virus vector 2

Fingerprint

Dive into the research topics of 'Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy'. Together they form a unique fingerprint.

Cite this